2023 Access DEA 
The Blunt Truth
DECEMBER 29, 2023
We thought the market would expand “quite a bit” in 2023 – well, the “a bit” part was right. And not to ruin the ending, but no retail market will open in 2023. As of now, this is still a proposal, and it’s anyone’s guess if the DEA (who would do the actual re-scheduling) will think that’s a good idea. by a large margin.
Cannabis Law Report
AUGUST 12, 2022
Marijuana Moment report on some of the panels being proposed for 2023…… Voting is now open for the public to decide which panels will make the stage at next year’s South By Southwest (SXSW) festival—and there are about 100 marijuana- and psychedelics-related proposals to pick from. Which Political Party Will Legalize Weed?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 4, 2021
Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Access Pursuant to the Oregon Psilocybin Services Act. Access to Psilocybin Therapy Pursuant to Right to Try Laws.
Veriheal
MARCH 6, 2024
Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. Speaking about research and development, think about all the new cannabis studies that can happen when you allow researchers to more easily access the plant.
Veriheal
DECEMBER 27, 2022
In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. . It’s excellent news, particularly since new research suggests psilocybin deserves further investigation.
SpeedWeed
MAY 15, 2021
Doblin and his fellow researchers initially began exploring the therapeutic potential of MDMA back in the early 1980s, but these studies ground to a halt when the DEA banned ecstasy in 1985. MAPS is now enrolling participants for a further Phase 3 study that will allow another 50 subjects to access this promising new therapy.
Cannabis Law Report
MAY 31, 2022
The only opportunity to currently participate would be through an active clinical trial or via an argument under the Right to Try Act of 2018 (an act which provides a pathway for patients with life-threatening diseases or conditions to access unapproved treatments). Emerging Non-Medical State-Regulated Path. Non-Commercial Operations.
Expert insights. Personalized for you.
52 
Let's personalize your content